On Wednesday, the Food and Drug Administration issued a warning, calling compounded GLP-1 medications "risky for patients." "FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss," the FDA said
Caiafa, P., Guastafierro, T
However, the researchers said they did not establish a dose-dependent improvement, meaning that individuals who took more of the drug did not see better results than those who took less of it
A one-size-fits-all protocol is not a substitute for individualized care
The more you order, the better your deals get